Inhibitors of redox signaling and methods of using same

Details Inhibitors of redox signaling and methods of using same Inhibitors of redox signaling and methods of using same

1998-07-31

2002-04-16

Travers, Russell (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S397000, C514S398000, C514S399000, C514S400000, C514S375000

Reexamination Certificate

active

06372772

ABSTRACT:

BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to agents which inhibit or interfere with cellular redox systems as well as to the utilization of these agents as diagnostic tools and/or therapeutic agents. More specifically, the present invention relates to agents which interfere with or inhibit a thioredoxin/thioredoxin reductase redox system.
2. Background of the Related Art
Cellular redox systems appear to be very important to normal cellular activity. Cells maintain an intracellular environment that is reducing in the face of a highly oxidizing extracellular environment. Regulated alterations in the intracellular redox state (redox signaling) can modulate events such as DNA synthesis, enzyme activation, selective gene expression, regulation of cell cycle, cell growth, and programmed cell death.
One of the more important consequence of intracellular redox signaling is a change in the oxidative state of select cysteine residues on certain proteins. The post-translational modification of cysteine is difficult to follow since it lacks a convenient marker and is readily reversed when the cell contents are exposed to extracellular oxidizing conditions.
One type of abnormal cell function is abnormal cellular proliferation. Abnormal cellular proliferation is a cardinal feature of human malignancy. During the past decade there has been much insight into the biomolecules that regulate cell proliferation and the pathways in which they operate. These biomolecules have been identified as pharmacological, therapeutic, and/or diagnostic targets for agents which inhibit cellular proliferation.
Another type of abnormal cell function is resistance to apoptosis. Apoptosis is a form of programmed cell death characterized by membrane blebbing, chromatin margination and breakdown of chromosomal DNA into nucleosome-sized fragments. Programmed cell death or apoptosis is an important event in the normal processes of development and tissue remodeling. Loss of apoptosis can lead to diseases associated with cellular proliferation, such as cancer autoimmune disease, inflammation and hyperproliferation disease, while increased apoptosis can lead to neurodegenerative disease and destruction of tissue, as well as cardiovascular damage. Normally, when a cell sustains substantial genetic damage that cannot be repaired by normal DNA repair processes, this is recognized by sensory mechanisms in the cell and a sequence of events is initiated which leads to the death of the cell. Apoptosis results in the death of individual damaged cells and protects the organism from potentially harmful genetic changes that could lead to unregulated cell growth including cancer. Apoptosis resistance has been correlated with induction of the cylcin-dependent kinase inhibitor. There are now documented instances where inhibition of apoptosis by the abnormal expression of an oncogene or the loss of a tumor suppresser genes are closely associated with malignancy. It also appears that as cells develop from a nontransformed state, through a pre-malignant to a fully transformed state, they progressively lose their ability to undergo apoptosis. Apoptosis is also inhibited by some viral infections, in auto immune disease and hyperproliferative skin diseases.
Discovery of molecules which interfere with or inhibit cellular redox systems satisfies a need in the art by providing new diagnostic or therapeutic compositions useful in the detection, prevention, and treatment of diseases related to abnormal cellular activity (i.e., proliferation and apoptosis). These diseases include cancer, viral and other infections, inflammatory diseases, cardiovascular disease, nuerodegenerative diseases, skin disease and immunological disorders.
SUMMARY OF THE INVENTION
Proteins and enzymes involved in the cellular redox reaction provide an attractive site for the development of therapies, diagnostic, and assays for diseased states associated with abnormal cellular function. These agents may serve as chemotherapeutic agents themselves or may increase the efficacy of existing chemotherapeutic agents. Because of the close interactions between intracellular signaling pathways for proliferation and death, effective and selective inhibitors of cell proliferation may also cause desirable cell death.
Strategies for targeting redox related processes in the development of anticancer therapies can be subdivided into three main areas. First, there has been considerable activity in the exploitation of the hypoxic nature of solid tumors. Leading this charge is the search for bio-reductive drugs which will be metabolically activated in the hypoxic fraction. This effort has included the search for agents which will modify (both increase and decrease) the hypoxic fraction. A second approach attempts to alter enzyme levels or activities through gene therapy or induction by non-toxic agents. Finally, cellular signaling pathways having points of redox control have become the target of therapeutic or chemopreventitive intervention. Inhibitors of cellular redox or agents which interfere with cellular redox have strong potential applications as chemopreventative or chemotherapeutic agents.
The present invention is directed to inhibitors of redox signaling and a method of using these inhibitors for therapeutic or prophylactic treatment of a mammalian host caused by abnormal cellular function. The inhibitor(s) may be administered alone or in combination with other thereapeutic agents (e.g. other anti-cancer drugs).
This invention relates to a composition comprised of an inhibitor of cellular redox signaling, along with a pharmaceutically acceptable carrier of said inhibitor. It is preferable that the inhibitor(s) of cellular redox signaling also prevent inhibition of apoptosis. Preferably the inhibitor of cellular redox signaling inhibits or interferes with a thioredoxin redox system, and more preferably, the inhibitor of said thioredoxin system is an inhibitor of thioredoxin or an inhibitor of thioredoxin reductase.
The present invention also relates to a composition comprising or including an said inhibitor of cellular redox signaling with an IC
50
TR/Trx of less than about 50 &mgr;g/ml. Preferably the inhibitor of cellular redox signaling has an IC
50
TR/Trx of less than about 25 &mgr;g/ml, more preferably an IC
50
TR/Trx of less than about 10 &mgr;g/ml, even more preferably an IC
50
TR/Trx of less than about 5 &mgr;g/ml, and most preferably the inhibitor of cellular redox signaling has an IC
50
TR/Trx of less than about 1 &mgr;g/ml.
Preferably the inhibitor of cellular redox signaling is selected from the group consisting of NSC 401005, NSC 208731, NSC 382000, NSC 665103, NSC 617145, NSC 618605, NSC 622378, NSC 620109, NSC 163027, NSC 131233, NSC 665102, NSC 631136, NSC 681277, NSC 140377, NSC 603084, NSC 382007, NSC 635002, NSC 620358, NSC 657028, NSC 661221, NSC 622188, NSC 645330, NSC 350629, NSC 102817, NSC 626162, NSC 655897, NSC 267461, NSC 627124, NSC 610187, NSC 624982, NSC 664951, NSC 277293, NSC 608972, NSC 634761, NSC 664271, NSC 665878, NSC 625814, NSC 264054, NSC 652257, NSC 661225, NSC 637828, NSC 647546, NSC 655305, NSC 641396, NSC 668262, NSC 662781 and NSC 626678.
The present invention also relates to a composition comprised of a therapeutically effective amount of an agent which inhibits cellular redox signaling wherein the agent also prevents inhibition of apoptosis. Preferably the agents has an IC
50
TR/Trx in the range of about 10 &mgr;g/ml to about 25 &mgr;g/ml, more preferably an IC
50
TR/Trx in the range of about 5 &mgr;g/ml to about 10 &mgr;g/ml, even more preferably an IC
50
TR/Trx in the range of about 1 &mgr;g/ml to about 5 &mgr;g/ml, and most preferably in a range of about 0.0001 &mgr;g/ml to about 1 &mgr;g/ml.
The invention also relates to a composition comprised of an inhibitor of cellular redox signaling and a pharmaceutically acceptable carrier, wherein the inhibitor of cellular redox signaling is selected from the group consisting of NSC compounds identified herein and preferably wherein

Affiliated with

Also associated with

Rating

Inhibitors of redox signaling and methods of using same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of redox signaling and methods of using same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of redox signaling and methods of using same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2900117